Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
NCT06271616 · Mayo Clinic · PHASE2 · terminated · last registry update 2026-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “poor accrual” | – | Registry record, Mayo Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BTK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-06Phase 3 first posted: Sanofi, rilzabrutinib + placebo (NCT07923305)
- 2026-10-27Phase 3 first posted: Beijing InnoCare Pharma Tech Co., Ltd., Orelabrutinib + ICP-248 (NCT07896590)
- 2026-10-21Results posted on the registry: AbbVie, Venetoclax + Ibrutinib (NCT05105841)
- 2026-10-14Results posted on the registry: Fred Hutchinson Cancer Center, Acalabrutinib (NCT04198922)
- 2026-09-25Results posted on the registry: Loxo Oncology, Inc., Pirtobrutinib + Bendamustine (NCT05023980)
- 2026-09-22Results posted on the registry: Dana-Farber Cancer Institute, Obinutuzumab + Ibrutinib (NCT02537613)
- 2026-09-01Results posted on the registry: AstraZeneca, Acalabrutinib (NCT04008706)
- 2026-08-25Phase 3 first posted: Beijing InnoCare Pharma Tech Co., Ltd., ICP-248 + Pirtobrutinib (NCT07784101)
- 2026-08-18Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Ibrutinib + Obinutuzumab (NCT03198026)
- 2026-08-06Results posted on the registry: Sanofi, rilzabrutinib + placebo (NCT05107115)
- 2026-07-29Phase 3 first posted: Pfizer, Ritlecitinib 100 mg + Ritlecitinib 50 mg (NCT07733765)
- 2026-07-22Results posted on the registry: Academic and Community Cancer Research United, Acalabrutinib + Bortezomib (NCT04626791)
- 2026-07-22Phase 3 first posted: Ruijin Hospital, Orelabrutinib + obinutuzumab (NCT07719855)
- 2026-07-15Results posted on the registry: Emma Guttman, PF-06651600 (NCT05549934)
- 2026-07-13Results posted on the registry: Sanofi, Placebo + Rilzabrutinib (NCT05018806)
- 2026-06-25Results posted on the registry: University of Washington, Acalabrutinib + Axicabtagene Ciloleucel (NCT04257578)
- 2026-06-10Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Acalabrutinib (NCT04548648)
- 2026-06-09Phase 3 first posted: The First Affiliated Hospital of Soochow University, Acalabrutinib maleate + bortezomib (NCT07635511)
- 2026-06-09Results posted on the registry: University of California, Davis, Blinatumomab + Ibrutinib (NCT02997761)
- 2026-05-22Results posted on the registry: University of California, San Diego, Ibrutinib 560mg PO daily (Imbruvica) + Cetuximab (NCT03646461)
- 2026-05-22Also stopped (terminated): University of California, San Diego, Ibrutinib 560mg PO daily (Imbruvica) + Cetuximab (NCT03646461)
- 2026-05-05Also stopped (terminated): Mayo Clinic, Ibrutinib + Ixazomib Citrate (NCT03506373)
- 2026-04-30Phase 3 first posted: Shandong University, High-Dose Dexamethasone Combined with Orelabrutinib + High-Dose Dexamethasone Combined with Placebo (NCT07559331)
- 2026-04-27Also stopped (terminated): Xuanwu Hospital, Beijing, zanubrutinib (NCT05356858)
- 2026-04-07Phase 3 first posted: Nurix Therapeutics, Inc., NX-5948 + Pirtobrutinib (NCT07516093)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision